Pathway Genomics, a genetic testing laboratory specializing in genetic testing for nutrition and exercise response, inherited disease, prescription drug response and health condition risks, has received membership in the American Clinical Laboratory Association (ACLA). As the nation’s leading industry group to advocate lab interests with the U.S. Food and Drug Administration (FDA) and Congress, ACLA was created in 1971 and is committed to promoting public awareness about the value of laboratory services in preventing illness, diagnosing disease, and monitoring medical treatment.
“ACLA is proud to welcome Pathway Genomics as its newest member,” said Alan Mertz, president of ACLA. “Pathway Genomics is another example of our nation’s laboratories that are at the forefront of genetic testing and personalized medicine.”
In addition to Pathway’s ACLA membership, the San Diego-based company was recently accredited by the College of American Pathologists (CAP), and the recipient of a Certificate of Accreditation from the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid, under the Clinical Laboratory Improvement Amendments (CLIA) of 1988.
“ACLA is an essential organization within the laboratory community,” said Jim Plante, Pathway’s founder and CEO. “The approval of our membership is representative of the importance of genetic testing, and the promise and value of personalized health care.”
Using saliva samples collected from patients, Pathway provides genetic tests for drug responses, nutrition and exercise response, inherited genetic conditions, and risk of many diseases. Pathway consists of more than 40 scientific and medical professionals, including medical doctors, molecular geneticists, and genetic counselors, as well as an expert scientific advisory board.
About Pathway Genomics
Pathway Genomics owns and operates an on-site genetic testing laboratory
that is accredited by the College of American Pathologists (CAP), accredited in accordance with the U.S. Health and Human Services’ Clinical Laboratory Improvement Amendments (CLIA) of 1988, and licensed by the state of California. The company uses customized and scientifically validated genetic testing technologies to generate personalized genetic reports, which address a variety of genetic issues, including an individual’s carrier status for recessive genetic conditions, food metabolism and exercise response, prescription drug response, and propensity to develop certain diseases, such as heart disease, type 2 diabetes, and cancer. Pathway’s services are available to patients through their physicians and select health management programs.